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Objective: The objective of this study was to measure the protein-specific
response of r1 and r2 relaxivities of commercially available gadolinium-based
magnetic resonance imaging contrast agents to variation of plasma-protein
concentrations.
Materials and Methods: In this in vitro study, contrast agent (gadofosveset
trisodium, gadoxetate disodium, gadobutrol, and gadoterate meglumine)
dilution series (0-2.5 mmol Gd/L) were prepared with plasma-protein (human se-
rum albumin [HSA] and immunoglobulin G [IgG]) concentrations at physiological
(42 and 10 g/L HSA and IgG, respectively, Normal) and at 3 pathological levels
with HSA/IgG concentrations of 10/10 (solution Alb low), 42/50 (IgG mild ), and
42/70 (IgG severe) g/L. Contrast-agent molar relaxivities and relaxivity-enhancing
proteinYcontrast-agent interaction coefficients were determined on the basis of
inversion-recovery and spin-echo data acquired at 1.5 and 3.0 Tat 37-C. Protein-
induced magnetic resonance imaging signal changes were calculated.
Results: The effective r1 and r2 molar relaxivities consistently increased with
albumin and IgG concentrations. At 1.5 T, the r1 values increased by 10.2
(gadofosveset), 4.3 (gadoxetate), 1.3 (gadobutrol), and 1.1 L sj1 mmolj1
(gadoterate), respectively, from the Alb low to the IgG severe solution. At 3.0 T,
the r1 values increased by 2.9 (gadofosveset), 2.3 (gadoxetate), 0.7 (gadobutrol),
and 0.9 (gadoterate) L sj1 mmolj1, respectively. An excess of IgGmost strongly
increased the r1 of gadoxetate (+40 and +19% at 1.5 and 3.0 T, respectively, from
Normal to IgG severe). An albumin deficiency most strongly decreased the r1 of
gadofosveset (j44% and j20% at 1.5 and 3.0 T, respectively, from Normal to
Alb low). The modeling confirmed a strong gadofosveset r1 enhancement by
albumin and suggested stronger IgG than albumin effects on the apparent molar
relaxivity of the other agents per protein mass concentration at 1.5 T.
Conclusions: Pathological deviations from normal plasma-protein concentra-
tions in aqueous solutions result in changes of effective r1 and r2 contrast-agent
relaxivities and projected signal enhancements that depend on the contrast
agent, the blood-serum protein profile, and the field strength.
Key Words: contrast-enhanced MR imaging, gadolinium-based contrast
agents, contrast-agent relaxivity, relaxometry, human blood serum proteins
(Invest Radiol 2014;49: 608Y619)
Gadolinium-based magnetic-resonance (MR) contrast agents(GBCAs) are administered in a large number of clinical exami-
nations worldwide.1 They provide morphological and functional in-
formation in a broad range of clinical settings by shortening recovery
times T1 and T2 of longitudinal and transverse water magnetization in
their close proximity, which can be exploited to depict corresponding
regions with increased or reduced signal intensity, respectively.
The effect strength, with which a contrast agent changes re-
laxation times and MR imaging signal intensities, is quantitatively
given by its longitudinal and transverse molar relaxivities, r1,and r2,
respectively.2
It is well known that GBCA relaxivities depend on concen-
tration of proteins, such as human serum albumin (HSA).3Y6 Some
agents were specifically designed to strongly interact with albumin to
increase their effective relaxivity in blood and other body fluids.7Y9
Therefore, it seems likely that pathological deviations from normal
protein concentrations cause signal changes in contrast-enhanced MR
imaging. It is not clear though whether such effects could be large
enough to impact diagnoses, given a sufficiently unusual combination
of contrast medium, image acquisition, data evaluation, and patholog-
ical protein profile.
The objectives of our study were to quantitatively measure ef-
fective r1 and r2 molar relaxivities of 4 commonly used commercially
available GBCAs in sodium-chloride solutions and in the presence of
physiologically and pathologically abnormal plasma-protein (HSA and
F-immunoglobulin G [IgG]) concentrations at 2 field strengths and to
use these values to project the expected signal response for some
commonly used MR imaging pulse sequences.
MATERIALS AND METHODS
Dilution Series
Stabilized solutions of human albumin and human IgG (20%
each, CSL Behring, Bern, Switzerland) were mixed with sterile 0.9%
aqueous sodium chloride to produce 5 protein stock solutions at
varying protein concentration: Normal solution, 42 g/L of albu-
min and 10 g/L of IgG; Alb low, 10/10; IgG mild, 42 /50; IgG severe,
42/70 g/L; NaCl only, 0/0.
Contrast media solutions at 0.25 mol Gd/L were obtained,
where required after dilution with aqueous sodium chloride: that of
gadofosveset trisodium (0.25 mol/L, Ablavar; Lantheus Medical
Imaging, N. Billerica, MA), that of gadoxetate disodium (0.25 mol/L,
Primovist; Bayer Healthcare, Leverkusen, Germany), gadobutrol (1 mol/L,
Gadovist; Bayer Healthcare), and that of gadoterate meglumine
(0.5 mol/L, Dotarem; Guerbet AG, Roissy, France), and diluted
with protein stock solutions to obtain dilution-series stock solutions
at 12.5 mmol Gd/L.
Repeatedly, an aliquot of 0.6mL of the dilution-series solution at
the current dilution step was diluted with 2.4 mL of the corresponding
protein stock solution to reach gadolinium concentrations of 2.5, 0.5,
0.1, 0.02, and 0.004 mmol Gd/L, respectively. The dilution series were
independently prepared twice. A total of 240 samples in 2-mL plastic
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vials were, in turn, collected in a rack that was inserted in a temperature-
controlled water-tank phantom for imaging (Fig. 1).
Laboratory Analyses
The total protein concentration of the protein solutions was
determined by the Biuret reaction10 on a Cobas Integra 800 analyzer
(Roche Diagnostics, Basel, Switzerland). Protein electrophoresis was
performed on an alkaline-buffered (pH, 8.6) agarose gel (Sebia
Hydragel Protein(E) K20, Sebia, Lisses, France), applying a voltage
of 90 V for 18 minutes. Immediately after the electrophoresis, the
fractionated proteins were fixed (60% ethanol, 10% acetic acid, and
30% deionized water) and stained with amido black solution for
4 minutes. The excess of stain was removed from the gel by 3 suc-
cessive baths of an acidic destaining solution (pH, 2). The gel was
dried, and electrophoresis curves were obtained by densitometric
scanning of the dried gel.
MR Imaging and Determination of Relaxation Rates
Data were acquired in clinical whole-body MR scanners op-
erating at 1.5 and 3.0 T (Signa HDxt and Discovery MR750, re-
spectively; GE Healthcare, Waukesha, WI) using transmit-receive
‘‘QUADKNEE’’ knee coils. During image acquisition, the water
phantom was kept at a constant temperature of 37-C with water cir-
culating through a temperature-controlled bath.
Longitudinal Relaxation Rates, R1
Two-dimensional inversion-recovery fast-spin-echo images were
acquired with varying inversion times (TIs) and constant preYscan para-
meters. Parameters at 1.5 Tare as follows: echo time (TE), 6.3 milliseconds;
repetition time (TR), 6000 milliseconds; echo-train length, 2; receive
bandwidth (RBW), T41.7 kHz; matrix size, 256  512; in-plane voxel
dimensions, 0.39  0.39 mm; slice thickness (THK), 8 mm; and TIs
of 50, 60, 80, 100, 120, 140, 180, 200, 400, 600, 1000, 1500, 2000, and
3000 milliseconds. Parameters at 3.0 T are as follows: TE, 10.4 milli-
seconds; TR, 6000 milliseconds; echo-train length, 2; RBW, T15.6
kHz; matrix size, 128  256; in-plane voxel dimension, 0.78  0.78
mm; THK, 8 mm; TI, as those on the 1.5-T scanner. T1 constants were
obtained from fits of the expression S0  (1 j 2  Exp(j TI/T1)) to
the experimental data, using custom MATLAB (MathWorks, Natick,
MA) code. R1 rates were obtained as 1/T1. T1 values shorter than
80 milliseconds and longer than 5 seconds were excluded from further
analyses. This led to an exclusion of mostly data points of the protein-
binding contrast agents gadovosfeset and gadoxetate at the highest
concentration, that is, 2.5 mM, at both field strengths. The total
number of data points in each fit is listed in Table 2.
Transverse Relaxation Rates, R2
Two-dimensional spin-echo images were acquired with vary-
ing TEs and constant preYscan parameters. Parameters at both field
strengths are as follows: TR, 7500 milliseconds; RBW, T15.6 kHz;
matrix size, 192  256; in-plane voxel dimensions, 0.78  0.78 mm;
THK, 8 mm; and TE times of 20, 50, 100, 400, and 800 milliseconds.
T2 constants were obtained from fits of the expression S0 
Exp(jTE/T2) + N to the experimental data, as above for T1 constants.
T2 values shorter than 20 milliseconds and longer than 5 seconds
were excluded from further analyses. R2 rates were obtained as 1/T2.
For the NaCl only solutions, without proteins, this led to the exclu-
sion of some data points at one or more of the 3 lowest gadolinium
concentrations (0-0.02 mM), whereas, for the protein solutions, it
tended to exclude data points at the 2 highest contrast-agent con-
centrations, particularly so for the protein-binding contrast agents.
The total number of data points in each fit is listed in Table 2.
Contrast-Agent Relaxivities
The apparent or effective molar relaxivities, reff1 , r
eff
2 , at a
given protein concentration, were estimated from the relaxation rates
R1,2(c) measured at different contrast-agent concentrations, c, ac-
cording to equation [1], by linear regression. These data served as
reference during the evaluation and are not shown. The reported ef-
fective molar relaxivities were obtained from the results of fits of
equation [2], as detailed below.
R1ðcÞ ¼ Rpre1 þ ref f1 *c;
R2ðcÞ ¼ Rpre2 þ ref f2 *c;
½1
FIGURE 1. A, The experimental setupwith the acrylic water-tank phantom that was attached to plastic tubes circulating 37-Cwater
from a thermo-regulated water bath outside the scanner room. The phantom was sealed during the experiments with an acryl
cover attached with plastic screws. B to E, Representative MR images: B and C, Inversion recovery fast spin-echo images at TI of 50
and 1000 milliseconds, respectively. D and E, Spin-echo images at TE of 20 and 100 milliseconds, respectively. Contrast-agent
concentrations decrease from the vials in the upper parts of the pictures to the lower part. The lowest row of vials contains
solutions of the control series without serum proteins. Slight Gibbs’ ringing artifacts may be noted at interfaces with high
signal-intensity changes.
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Relaxivity-Enhancement Model
The effective molar relaxivities, reff1;2 , and preYcontrast relax-
ation rates Rpre1;2 in equation [1] depend on protein concentrations.
3Y9
A more general signal equation should take that into consideration.
Thus, pooled relaxation rates of a contrast-agent dilution series at a
given field strength, at all protein concentrations levels and from both
dilution series, were fitted by least-square linear regression to the
following expressions:
R1ðc; cHSA; cIgGÞ ¼ Rpre10 þ rHSA1 cHSA þ rIgG1 cIgG þ ðrH2O1 þ reHSA1 cHSA þ reIgG1 cIgGÞc;
R2ðc; cHSA; cIgGÞ ¼ Rpre20 þ rHSA2 cHSA þ rIgG2 cIgG þ ðrH2O2 þ reHSA2 cHSA þ reIgG2 cIgGÞc; ½2
where c is the contrast-agent concentration and cHSA and cIgG are
albumin and IgG concentrations, respectively. Equation [2] expands
the relaxivities from equation [1] according to the following:
ref f1 ¼ rH2O1 þ reHSA1 cHSA þ reIgG1 cIgG;
ref f2 ¼ rH2O2 þ reHSA2 cHSA þ reIgG2 cIgG;
½3
with the ‘‘zero-protein contrast-agent relaxivities,’’ rHSA1;2 , r
IgG
1;2 ,
and the relaxivity-enhancement coefficients reHSA;IgG1;2 . Equation [2]
expands the preYcontrast relaxation rates from equation [1] according
to the following:
Rpre1 ¼ Rpre10 þ rHSA1 cHSA þ rIgG1 cIgG
Rpre2 ¼ Rpre20 þ rHSA2 cHSA þ rIgG2 cIgG;
½4
with the protein relaxivities rHSA1;2 and r
IgG
1;2 and the ‘‘zero protein,
preYcontrast relaxation rates’’ R10;20.
When setting both protein concentrations to zero, equation [2]
takes on the form of equation [1]. Equation [2] allows all data points
for a given combination of field strength and contrast agent to be
considered in a single fit, which resulted in an improved numerical
fit stability, compared with repeated isolated fits of equation [1]
to partial data. It also allows a phenomenological differentiation
of protein-specific effects on both native relaxation rates and on
contrast-agent molar relaxivity values. Finally, it allows straightfor-
ward interpolation and extrapolation compatible with our results to
other protein concentrations.
Equation [2] still assumes a linear relationship between re-
laxation rates and gadolinium concentration, which is known to not
always be correct. Nevertheless, we chose to work with equation [2]
to keep the model simple and the number of fitted variables as small
as possible, avoiding an ‘‘overfitting’’ of the data, and to be able to
discuss the results for the different contrast agents in a single approxi-
mate model that has been used in a large body of previous literature.
Compare the Results and Discussions sections for corresponding lim-
itations. The fits of equation [2] to experimental relaxation rates were
done with custom Python routines (Python Software Foundation,
Beaverton, OR) based on scikit-learn.11
Simulated Effects on MR Imaging Signal
Signal-intensity profiles were calculated for the following 1.5-T
MR imaging sequences with custom MATLAB routines:
a) MR angiographic blood-pool T1-weighted spoiled gradient-echo
signal, as (Sin5 (1 j E1) E2) / (1 j Cos5 E1); E1 = Exp(jTR
R1), and E2 = Exp(jTE R2), TR = 3.4 milliseconds, TE = 1.4
milliseconds, 5 = 25 degrees.
b) Tissue T1-weighted spin-echo signal, as (1 j E1) E2; TR = 500
milliseconds, TE = 10 milliseconds.
c) Tissue T2-weighted spin echo signal, as (1 j E1) E2; TR = 6000
milliseconds, TE = 100 milliseconds.
d) Generic tissue T2-weighted sequence signal, as in, for example,
dynamic-susceptibility contrast MRI, as (1 Y E1) E2; TR = 2000
milliseconds, TE = 50 milliseconds.
For (a) blood, relaxation times T1 and T2 of 1441 and
327 milliseconds12 were used; for (b) to (d) ‘‘tissue’’ T1 and T2 of
1000 and 100 milliseconds.
Statistical Analysis
Squared linear regression coefficients and root mean squared
errors were calculated for all fits. Plots of fit-residuals versus ex-
perimental relaxivity values were checked for systematic deviations.
The 90% confidence interval limits for the results of the relaxivity-
modeling fits were estimated by the bootstrap method.13
RESULTS
Laboratory Analyses
The differences between measured minus targeted protein con-
centrations were between 1% and 5% and, thus, not significant, con-
sidering the coefficient of variation of the used laboratory method of
2.5%. Electrophoresis curves are displayed in Figure 2. Qualitatively,
the relative amounts of the albumin and the F-globulin fractions from
electrophoresis were consistent with the targeted physiological situation
(Normal), hypoalbuminemia (Alb low), as well as mild (IgG mild) and
severe (IgG severe) gammopathy, respectively.
Relaxation Rates
Sample images used for the relaxation-rate determinations are
shown in Figure 1. Representative data points and exponential fits are
shown in Figure 3. Figure 4 displays plots of relaxation-rate en-
hancements versus gadolinium concentration as observed for all
contrast agents in the Normal protein-content solutions of dilution
series 1. Figure 5 shows plots of relaxation-rate enhancements versus
gadolinium concentration as observed for gadofosveset in the solu-
tions with different protein contents in dilution series 1. Both axes in
Figures 4 and 5 have a logarithmic scaling to emphasize deviations
from a linear dependence of the gadolinium concentration. Such
deviations were particularly prominent for transverse relaxation and
the protein-binding contrast agents, whereas the linear model ap-
proximated enhancement of longitudinal relaxation within the con-
centration range of interest well.
Relaxivity-Enhancement Fits
Results from the pooled fits of equation [2] are summarized in
Tables 1 and 2, compared below for more details. Plots of residuals
versus average of experimental and fit data for all fits (see Supplemental
Figure 1, Supplemental Digital Content 1, http://links.lww.com/RLI/A149)
and, specifically, for the fits of gadofosveset (see Supplemental Figure
2 [Supplemental Digital Content 2, http://links.lww.com/RLI/A150],
Supplemental Figure 3 [Supplemental Digital Content 3,
http://links.lww.com/RLI/A151], Supplemental Figure 4 [Sup-
plemental Digital Content 4, http://links.lww.com/RLI/A152],
and Supplemental Figure 5 [Supplemental Digital Content 5,
http://links.lww.com/RLI/A153]) did not reveal major overall
systematic deviations.
Contrast-Agent Relaxivities
The effective molar relaxivities at a given protein concentra-
tion, as defined by equation [1], are listed in Table 1 and graphically
visualized in Figure 6. These values were calculated from the fit re-
sults shown in Table 2, with the formula given in equation [3]. At
low total protein concentrations (NaCl only, Alb low, and Normal),
the 3.0-T reff1 and r
eff
2 relaxivities were slightly higher than the cor-
responding 1.5-T values, whereas, at higher protein concentrations
(IgG mild and IgG severe), the opposite was observed. The same
behavior was also observed in direct fits of single dilution-series data
at a given protein concentration.
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Protein-Induced Changes of Contrast-Agent
Relaxivities
Absolute and relative relaxivity changes from Normal to
pathology-mimicking protein solutions are also summarized in Table
1. In general, higher protein content correlated with increased r1 and
r2 relaxivities and lower protein content correlated with decreased r1
and r2 relaxivities. The largest decreases versus the Normal solutions
were found for the NaCl only solution, that is, upon removal of physi-
ological amounts of albumin and IgG. The largest relative negative
changes were found for gadofosveset. Negative changes were also
found for the hypoalbuminemia solution Alb low. In contrast, positive
changes were observed for both mild and severe gammopathy solutions
IgG mild and IgG severe. The largest relative positive changes were
observed for gadoxetate.
Protein-Specific Relaxivity Enhancement
Large contrast-agent relaxivity-enhancing coefficients reHSA1
and reHSA2 that were significantly larger than corresponding co-
efficients reIgG1 and re
IgG
2 were found for gadofosveset (Table 2). In
contrast, in most cases for the other contrast agents, the corresponding
FIGURE 2. Densitogram of the electrophoresis of the 4 solutions with varying serum protein content: physiological (Normal)
solution (A) and the solutions mimicking hypoalbuminemia (Alb low, different scaling than in A) (B) as well as mild (IgG mild) (C),
and severe (IgG severe) gammopathy (D). Note the absence of >- and A-globulin components from all solutions (A-D).
FIGURE 3. Exemplary inversion-recovery curves (R1 quantification) and transverse relaxation curves (R2 quantification) from the
first dilution series at 3 T of gadofosveset and gadoterate, Normal solution.
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FIGURE 4. Relaxation-rate changes induced by the 4 contrast agents at physiological albumin and IgG content, that is, in the
Normal solutions of dilution series 1; $R1 (A, C) and $R2 (B, D) values at 1.5 T (A, B) and at 3.0 T (C, D), respectively.
FIGURE 5. Relaxation-rate changes induced by gadofosveset as observed in dilution series 1; $R1 (A, C) and $R2 (B, D) values at
1.5 T (A, B) and at 3.0 T (C, D), respectively.
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IgG coefficients were at least as large as the albumin coefficients, par-
ticularly those describing transverse relaxation effects, reIgG2 .
Protein Relaxivity
The coefficients assessing direct effects of the proteins on
longitudinal relaxation, rHSA;IgG1 , were negligibly small at both field
strengths (Table 2). In contrast, rHSA;IgG2 values indicated a direct in-
fluence of both proteins on transverse relaxation rates, even in the
absence of any contrast agent. Immunoglobulin G had a larger influ-
ence than did albumin.
Simulated Effects on MR Imaging Signal
Simulated signal curves for common MR imaging sequences
are shown in Figures 7 to 10. The gadofosveset-induced signal
change strongly depended on the albumin level for all sequences,
whereas the influence of IgG was noticeably smaller. In distinction,
FIGURE 6. Graphical representation of effective molar relaxivities r1 and r2 of 4 GBCAs at magnetic field strengths of 1.5 T and
3.0 T at varying serum-protein content, compare Table 1 for numerical values. Note the different ordinate scales. Error bars
indicate 90% confidence intervals.
FIGURE 7. Simulated MR angiography signal as a function of the contrast-medium and human serum-protein concentrations
(TR/TE/flip angle, 3.4 milliseconds/1.4 milliseconds/25 degrees; precontrast, 1.5 T (blood) T1/T2, 1441/327 milliseconds).
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gadoxetate-induced MR signal changes strongly depended on both
albumin and IgG concentration levels. For MR angiography, the most
robust signal enhancement with the smallest protein-induced varia-
tion was projected for gadobutrol and gadoterate. The T2-weighted
signal decrease to be expected in, for example, dynamic susceptibility-
weighted imaging noticeably depended upon protein concentrations for
all evaluated contrast agents.
DISCUSSION
The present investigation demonstrates that common patho-
logical deviations from normal blood-serum protein concentration
levels alter the signal enhancement induced by gadolinium-based
MR contrast agents. Protein-level deviations of an extent that may
be found in daily clinical practice in patients with liver failure,
chronic inflammation, or multiple myeloma14 caused large changes
of the relaxation rates of our test solutions, that of the contrast-agent
relaxivities, and that of the projected MR imaging signal intensities.
An albumin deficiency decreased the relaxivities of all con-
trast agents, with gadofosveset showing the largest relative reduction.
In contrast, the pathological elevation of IgG levels increased the
relaxivities of all contrast agents, with gadoxetate showing the largest
relative increase. The results translate into signal-intensity changes in
contrast-enhanced MR imaging that, however, strongly depend on the
type of the acquisition sequence, the field strength, as well as the type
and concentration of the contrast agent.
Our study demonstrates significant effects of pathological IgG
protein levels on contrast-agent relaxivities and quantifies contrast-
agentYmediated as well as direct effects of albumin and IgG on
water-proton relaxation rates. Equation [2] represents the simplest
model capable of summarizing and repredicting our experimental
data by accounting for a direct influence of each protein on preY
contrast native relaxation rates and on contrast-agent relaxivity.
Protein-contrast agent interactions have been modeled with more
sophisticated equations before, for example, in the studies of Caravan8
or Henrotte.15 However, those require information or assumptions on
the contrast-agent protein interaction, for example, the number of
independent interaction sites, and could not reproduce the obvious
influence on the transverse preYcontrast relaxation rates that albu-
min and, in particular, IgG exerted in our study. Equation [2] still
assumes the relaxation enhancement to linearly grow with contrast-
agent concentration. As Figures 4 and 5 demonstrate, this is a somewhat
crude model for the observed transverse relaxation-rate enhancement,
whereas it seems mostly satisfactory for the description of the longi-
tudinal relaxation-rate enhancement.
It is well established that molar contrast-agent relaxivity in-
creases with protein content.2,5,16,17 In the current study, IgG pro-
duced even larger effects per mass concentration, at least at 1.5 T,
than albumin did, except for the contrast agent that specifically binds
to albumin (gadofosveset). Proteins are believed to exert their influ-
ence by a slowing down of molecular reorientation of water and
contrast-agent molecules and an increase in their orientational cor-
relation times. Underlying mechanisms are a protein-induced in-
crease in overall solution viscosity,6,18 an increased ‘‘microviscosity’’
in the protein hydration sphere, or a transient binding of the small
molecules with corresponding temporary slowdown of their molec-
ular tumbling.19,20
In the absence of detailed knowledge about specific in-
teractions and about 3-dimensional protein structure and accessible
surface area, one could expect larger proteins with longer molecular
FIGURE 8. Simulated T1-weighted spin-echo signal as a function of contrast-medium and human serum-protein concentrations
(TR/TE, 500 milliseconds/10 milliseconds; precontrast (tissue) T1/T2, 1000 milliseconds/100 milliseconds).
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reorientation times to exert a stronger influence because of a higher
increase in time-averaged molecular re-orientation times of tran-
siently bound smaller molecules.8,21 Because the IgG molecular mass
(approximately 150 kDa) is approximately 3 times as large as that of
albumin (67.5 kDa),22 IgG could, in agreement with our results, be
expected to exhibit larger effects on contrast-agent relaxivities than
albumin under the assumption of a nonYspecific weak binding and
an equal number of binding sites per protein mass. The effect size
of a smaller protein could reach or even surpass that of a non-
specifically binding larger protein if it offered a particular contrast
agent one or more tailored binding sites with optimally positioned
protein functional groups that strongly increase either polar or
nonYpolar attraction forces. This may well apply to the gadovosfeset/
albumin interaction and the corresponding large effects on water-
proton relaxation. In the light of this tentative explanation of our
results, even stronger effects, at least on transverse relaxivities, could
be expected for proteins that are significantly larger than IgG, for
example, immunoglobulin M.
It is not immediately clear how our in vitro results translate to
clinical in vivo imaging. Considering the strong effects, it seems
likely that, even in daily clinical practice, there will be a combination
of imaging protocol, pathology, and data evaluation, where de-
viations from physiological protein concentrations noticeably distort
the results. Assessment of parenchymal tissue perfusion based on
increased R2 relaxation rates during contrast-medium first pass,
where signal changes are quantitatively converted to contrast-agent
concentrations, may be a prime candidate for observation of such
effects, compare Figure 10, particularly when standardized arterial
input functions are used. Moreover, the protein-binding contrast agents
exhibit a different clearance behavior with significant excretion from
the liver compared with the predominant renal clearance of the
nonYprotein-binding contrast agents. If MR imaging is performed
with a significant delay after bolus injection, the different clearance
mechanisms may contribute to signal variations because of different
plasma concentration levels besides influencing extravasation and,
secondarily, also relaxivities in the interstitium according to local
protein concentrations.
Our study has the following limitations:
(a) Our solutions did not contain proteins of the >1, >2, and A-fractions
of a normal serum protein electrophoresis because we could
not obtain sufficient quantities of purified solutions. The >1-
and >2-fractions, which contain most of the acute-phase pro-
teins, and the A-fraction represent 1% to 4%, 7% to 13%, and 7%
to 13% of total protein under physiological conditions, respec-
tively, whereas F-globulins constitute 8% to 16% and albumin
constitute as much as 58% to 72%. Our protein solutions did not
contain other abundant immunoglobulin classes normally present
in serum either, such as immunoglobulin A and immunoglobulin
M. Immunoglobulin G is, however, the most abundant one, with a
serum concentration of 7 to 16 g/L, whereas IgA and IgM serum
concentrations are 0.7 to 4.0 g/L and 0.4 to 2.3 g/L, respectively.
Nevertheless, the previously mentioned missing proteins may interact
stronger with contrast agents than do albumin and IgG.
As can be seen from the electrophoresis densitograms, the
serum-protein profiles of our solutions resembled those of polyclonal
gammopathies, as found, for example, in the case of chronic in-
flammation. Monoclonal gammopathies, as found in monoclonal
gammopathy of undefined origin or multiple myeloma, give raise to
a sharp, well-defined band, often within the F-globulin fraction. The
overexpressed immunoglobulin molecule could possibly interact
stronger than IgG does in the current study.
FIGURE 9. Simulated T2-weighted spin-echo signal as a function of contrast-medium and human serum-protein concentrations
(TR/TE, 6000 milliseconds/100 milliseconds; precontrast (tissue) T1/T2, 1000 milliseconds/100 milliseconds).
Investigative Radiology & Volume 49, Number 9, September 2014 Protein-Specific Impact on Contrast-Enhanced MRI
* 2014 Lippincott Williams & Wilkins www.investigativeradiology.com 617
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
(b) Because of restrictions of MR scanner software and the overall
feasibility of the study, not all sequence parameters could opti-
mally be set. Specifically, the TR of 6000 milliseconds was too
short to allow full magnetization recovery in the T1 measure-
ments, and it was not increased with increasing TI. The minimum
TI was limited to 50 milliseconds. Systematic errors may have
resulted, for example, the slightly larger r1 relaxivities at lower
field strength for the dilution series with low and zero protein
concentrations. Also, in the T2 determination, for practicability
reasons, the number of TEs was limited to 6. Finally, we mea-
sured up to 36 vials simultaneously without explicit correction
of B1-field inhomogeneity. We believe that none of these had a
major impact on the overall results of reported protein-induced
relaxivity changes.
(c) Because we could only include a small number of albumin (2) and
IgG (3) concentrations in our study, we cannot exclude that
nonYlinear dependencies or more complicated interaction models
may need to be taken into account if more concentrations within
the pathologic range could be evaluated. However, our results
appeared rather stable in repeated evaluations with varying fit
parameters and showed clear and logical trends, largely in agree-
ment with previous literature reports, where such were available.
(d) We worked with ‘‘molar’’ gadolinium concentrations, in moles
gadolinium per liter solution, as opposed to molal (moles gadolini-
um per kilogram solvent) contrast-agent concentrations. Our pri-
mary focus was projected MR signal changes from a given volume
(voxel) with a given amount of gadolinium upon pathological
protein-content change. In this context, molar concentrations were
of a more direct interest and allowed a more direct comparison with
most previous studies comparing ‘‘molar’’ relaxivity data of multiple
contrast agents. For a study of the interactions of protein, contrast
agent and water on a molecular level and molal concentrations
would be advantageous. Such a detailed analysis was beyond the
scope of our phenomenological study.
(e) Because of constraints of measurement time, we were not able
to completely compensate for all Gibbs ringing effects in the
images, which, in principle, could have been compensated by
higher spatial resolution and subsequently longer acquisition time.
This study has been published in parts as a conference
abstract.23
In conclusion, deviations of plasma-protein concentrations in
aqueous solutions from physiological to pathological ranges result in
significant changes of effective contrast agent relaxivities and may
significantly alter the signal behavior of commonly applied MR im-
aging sequences.
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